Oxnard-based Cure Pharmaceutical saw big rise in revenue in the fourth quarter of 2020 as it integrates a major acquisition, but growing net losses and a dispute with a licensee could be obstacles going forward. Cure closed the acquisition of the CBD company Sera Labs on Oct. 2, according to Cure’s 2020 annual report, filed…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
